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Chapter 8 
An Affordable Catalyst for the Production of Amino 
Acids 
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Ben L. Feringa2, André H. M. de Vries3, Charlotte E. Willans3, 
Jeroen A. F. Boogers3, and Johannes G. de Vries2,3 
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2University of Groningen, Stratingh Institute, Nijenborgh 4, 
9747 AG Groningen, The Netherlands 
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Asymmetric hydrogenation has been demonstrated to 
be a useful synthetic approach to amino acids and 
derivatives. The asymmetric reduction step itself is 
usually straightforward, but the synthesis of the ligand 
that invokes the asymmetric induction can be difficult. 
Use of MonoPhos™, a phosphoramidite, allows for a 
low cost solution as it is derived in a single step from 
BINOL, an item of commerce available as either 
antipode. Rhodium catalyzed asymmetric 
hydrogenations proceed with high enantioselectivities, 
especially to substituted phenylalanine derivatives. A 
large solvent effect is observed. 
© 2004 American Chemical Society 115 
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Introduction 
Many ligands have been developed and advocated for the 
asymmetric reduction of enamides by a transition metal catalyst to α-
amino acid derivatives (Scheme 1) (1,2).  Most known ligands are 
bidentate.  The ligand’s chirality can be derived from stereogenic 
phosphorus atoms, as in the DIPAMP (1) system of Knowles, or from 
carbon stereocenters.  Examples are given in Figure 1.  There has also 
been a number of systems developed, of which BINAP (2) is the best 




Figure 1: Some examples of ligands used to effect asymmetric reductions. 
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Whatever the source of chirality, all these systems have a major 
drawback in that their synthesis is expensive, can involve a long 
sequence, be low yielding, or tedious.  Often a resolution has to be 
performed. In a few cases, as in BICP (3), the chirality originates from the 
chiral pool and access to the antipode can be problematic (3). In most 
papers on asymmetric hydrogenations, these problems are treated in a 
cursory manner or completely ignored.  To perform an asymmetric 
hydrogenation reaction at scale, the ligand synthesis can be the greatest 
problem that has to be overcome.  In addition, the emphasis on 
enantioselectivity is usually to the detriment of low catalyst usage, which 
can have a large impact on the economics of the process. The kinetics of 
the reaction are often ignored in publications, and these can also have a 
large effect on the economics of the process. 
Although Knowles’ catalyst has been known for almost thirty years, 
and has been used at industrial scale (2), there are still relatively few 
asymmetric hydrogenations performed at scale.  If we consider Knowles’ 
catalyst, which has been used for the production of L-Dopa  (Scheme 1; R 
= 3-AcO,4-MeOC6H3; cat = [Rh(DIPAMP)(COD)]BF4–), the synthesis of 
the ligand is long, low yielding (4) and tedious (5).  However, a wide 
range of enamides can be reduced and the method is useful for the 
production of unnatural amino acids as long as there is no substituent at 
the β-position (4).  The development of the DuPhos and related systems 
overcame the β-substituent problem, but again the synthesis of the ligand 
is not a trivial undertaking (6).  There is also a dogma that bidentate 
ligands are required to obtain high asymmetric induction. 
A recent survey by Blaser et al. shows that at best a dozen processes 
based on asymmetric hydrogenation have been implemented for the 
production of enantiopure intermediates on ton-scale (7). We believe that 
this scant use of such a well-studied technology is caused by the 
following main reasons: Time-to-market constraints often do not allow 
sufficient time to develop a catalytic process for new products. The costs 
of metal or ligand may be too high. The third reason can be poor 
availability of ligands (both lab and production scale) on short notice. 
The result of these problems in the fine chemical industry, especially for 
pharmaceutically related products, is that methodology that is easier to 
screen and implement is used in preference to asymmetric 
hydrogenations. 
MonoPhosTM reductions 
With the knowledge that there is still a need for better asymmetric 
hydrogenation   catalysts,   it    was    fascinating    that    phosphoramidite 
118 
derivatives of binaphthol (4) (BINOL) have been used to effect 
asymmetric conjugate additions to enones (8).  The ligand system, was 
therefore, tried in the context of an asymmetric hydrogenation as libraries 
of ligands could be prepared by a simple procedure (vide infra).  The 
common perception that a bidentate ligand is required for good 
asymmetric induction was found not to be the case. In addtion to the 
synthesis of α-amino acids, application of monodentate phosphoramidites 
in the rhodium catalysed hydrogenations of aromatic enamides (9) and 
dehydro-beta-amino acids (10) have recently been reported. 
The initial experiments to prepare α-amino acids were performed 
with the dimethylamino phosphoramidite, that has become known as 
MonoPhos™  (5). The model enamide is methyl α -N-
acetylamidocinnamate (6) (Scheme 2). 
Scheme 2. 
 
The initial findings were that there is a strong solvent effect.  Use of 
methanol provides moderate asymmetric induction but when methylene 
chloride is the solvent, excellent asymmetric induction is observed 
(Scheme 2 and Table I) (11,12).  The reaction also works well for a 
variety of substituted phenylalanine derivatives (Table II and Scheme 3) 
(13). 
The initial hydrogenation experiments were performed in Schlenk 
tubes at 1 bar using a small magnetic stirring bar. Rates of these reactions 
were not very high. However, upon transferring the hydrogenation into 
well-stirred autoclaves, and raising the pressure to 5 bar we could raise 
the turnover frequency (TOF) to 300 h–1 (Table II, Entry 3). At high 
pressure (60 bar)  an unoptimized TOF of 1667 h–1 has been achieved. 
Obviously, the reaction has a positive order in hydrogen pressure. Most 
gratifyingly we found that, unlike with many bisphosphine ligands, the 
enantioselectivity does not decrease with increasing pressure. 
A variety of substituents on the phenyl group in the substrate have 
little or no effect on the enantioselectivity of the hydrogenation, although 
the rate was affected significantly (Table II). 
Table I. Summary of enantioselectivity for the preparation of 
phenylalanine  from 6 as described in Scheme 2 with 1 bar of 
hydrogen.  
Solvent  Temp  ee (%)  
CH3OH  rta  70  
CH2Cl2  rt  95  
CH2Cl2  5°C  97  
THF  rt  93  
Me2CO  rt  92  
EtOAc  rt  95  
PrOCH2CH2OH  rt  77  
a




Table II. Reductions of substituted phenylalanine derivatives as 
shown in Scheme 3.13  
Entry  R  R1  Solvent  pH2 (bar)  Time  ee (%) 
1  H  H  CH2Cl2  5  3 h  97  
2  H  Me  CH2Cl2  1  3 h  95  
3  H  Me  CH2Cl2  5  40 min  95  
4  H  Me  EtOAc  1  2 h  96  
5  3-MeO  Me  CH2Cl2  5  2 h  97  
6  4-MeO  Me  CH2Cl2  5  2 h  94  
7  4-AcO, 3-MeO  Me  EtOAc  5  nda  96  
8  4-F  H  CH2Cl2  27  10 min  93  
9  4-F  Me  CH2Cl2  5  25 min  96  
10  3-F  H  CH2Cl2  10  2 h  96  
11  3-F  Me  CH2Cl2  5  30 min  95  
12  2-F  Me  CH2Cl2  5  15 min  95  
13  4-Cl  Me  CH2Cl2  5  20 min  94  
14  3,4-Cl2  H  CH2Cl2  5  2 h  97  
15  3,4-Cl2  Me  CH2Cl2  5  30 min  99  
16  3-NO2  Me  CH2Cl2  5  2 h  95  
17  4-NO2  Me  CH2Cl2  5  nd  95  
18  4-F, 3-NO2  Me  CH2Cl2  5  2 h  95  
19  4-Ph  Me  CH2Cl2  5  25 min  95  
20  3-F, 4-Ph  Me  CH2Cl2  5  25 min  93  
21  4-Ac  Me  CH2Cl2  5  15 min  99  
22  4-PhCO  Me  CH2Cl2  5  30 min  94  
23  4-CN  Me  CH2Cl2  5  18 h  92  
24  1-naphthylb  Me  CH2Cl2  5  10 min  93  
a
 Denotes not determined. bThis is the aryl substituent. 
Ligand synthesis 
Although MonoPhos™ is a monodentate ligand, good asymmetric 
induction is observed.  The power of this approach is that the ligand is 
readily available from BINOL (4) (Scheme 4) (14).  Other analogues 7 of 
MonoPhos™ are available by substitution of the amine moiety or by a 
short synthesis (Scheme 4) (15-17). 
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Scheme 4. 
The complex formation between the ligand and the metal can be 
performed prior to the reduction either as a separate step, or in situ.  The 
procedure alleviates some of the problems associated with oxygen 
sensitivity seen with other systems. 
Mechanistic considerations 
This aspect of the work is still ongoing. Many studies have appeared 
investigating the mechanism of rhodium-bisphosphine catalyzed 
asymmetric hydrogenation of dehydroamino acids (18). In the Halpern 
mechanism oxidative addition of hydrogen to the Rh-bisphosphine olefin 
complex is the rate-determining step (19,20). Recently, Imamoto has 
published evidence for the formation of a Rh-bisphosphine dihydride 
complex at low temperature, which has reopened the debate on the 
mechanism (21). 
122 
One of the more surprising characteristics of the use of monodentate 
phosphoramidites in rhodium-catalyzed hydrogenations is the effect of 
the ligand/rhodium ratio. Phosphoramidites bind very strongly to 
rhodium, in spite of their reduced sigma donating properties due to their 
greatly enhanced pi acceptor properties as compared to phosphines. It thus 
did not come as a surprise that catalytic activity ceased when the L/Rh 
ratio was increased to 3 (Figure 2) in the hydrogenation of 6. 
 
Figure 2: Rate dependence on the MonoPhos:Rh ratio for the reduction 
of 6 
However, when the ratio of 5:Rh was lowered to 1.5 or 1 we found 
an unexpected increase of the rate. Even more interesting was the finding 
that the ee remained the same over the whole L/Rh range from 1-2 
equivalents of MonoPhos:Rh and remained the same throughout the 
hydrogenation reaction. This suggests that a single rhodium species is the 
active catalyst in all these hydrogenations independent of the 5:Rh ratio. 
We have performed these experiments both at 1 bar with 5 mol% of 
catalyst and at 15 bar with 0.015 mol% of catalyst and found essentially 
the same results. Thus far we had assumed that in the entire catalytic 
cycle two ligands would be bound to rhodium. However, these results 
suggest that this may not be the case. 
To shed more light on this dilemma, we decided to perform a test for 
non-linear effects after the work of Kagan et al (22). We performed this 
test using MonoPhos™ (5) of varying degrees of enantiomeric purity in 
the rhodium-catalyzed hydrogenation of 6. As can be seen from Figure 3, 
we obtained a weak, but reproducible, positive non-linear effect. 
Although this definitely establishes the presence  of  complexes  with  two 
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or more ligands it still does not rule out the possibility that these 
complexes dissociate into a mono-ligated complex, which could be the 
actual catalytic species . It is clear that more information is necessary. 
Figure 3: Asymmetric amplification with MonoPhos. 
As a comparison a number of different ligands were prepared. One 
variation was changing of the nitrogen substituents (8,9). Hydrogenation 
of BINOL over PtO2 (23), followed by reaction with HMPT gave 10. The 
effect of substituents on the BINOL skeleton in the 6- (11) and 3-
positions (12) was probed. In addition, bridged systems with two 




13; n = 1, R = Me 
14; n = 2, R = i-Pr 
15; n = 2, R = (S)-PhMeCH 
The ligands were tested in the Rh-catalysed hydrogenation of a 
limited number of dehydrophenylalanine derivatives; most experiments 
were performed on 6. In the dehydroamino acid hydrogenations the two 
methyl substituents on nitrogen as in 5 are unsurpassed up to now. The 
6,6’-dibromo-MonoPhos 11 behaved very similar to MonoPhos in the 
hydrogenation of 6, although the rate is somewhat lower (Figure 4). 
Enantioselectivity did suffer when this ligand was applied for the 
hydrogenation of the 4-fluoro-derivative. The effect of the 3,3’-dimethyl 
substituents of 12 was more marked and led to a strongly reduced rate as 
well as a somewhat lower enantioselectivity in the hydrogenation of 6. 
Surprisingly, the configuration of the product is the same as that of the 
BINOL, in contrast to results with the other BINOL ligands. 
Hydrogenations with octahydro-MonoPhos 11 gave results that were 
comparable to those obtained with MonoPhos itself. This was recently 
confirmed by the work of Chan et al. (24). Use of bidentate ligands such 
as 13-15 was not so successful. In methanol hardly any reaction took 
place, although in CH2Cl2 a reasonable rate could be attained, depending 
on bridge length. Nevertheless, enantioselectivity was much lower than 
with the monodentate ligands. 
A comparison of the kinetics of the hydrogenation of 6 using ligands 
5, 10-12 is given in Figure 4. These traces represent hydrogen uptake 
during hydrogenation at 5 bar pressure that were performed 
simultaneously in the EndeavorTM, a semi-automated device which allows 
8 parallel gas-liquid reactions with continuous monitoring of hydrogen 
uptake. The first 30 minutes are used for repeated purging with N2. After 
the solution has been pressurised with H2 the reaction starts almost 
immediately and seemingly follows zero order kinetics with 5 and 10. 
Although hydrogenation using 11 is clearly slower the kinetic profile is 
very similar to that of 5 and 10. Quite different kinetics are observed with 
the 3,3’-dimethyl derivative 12; an induction period is apparent and after 
a much slower reaction the rate gradually decreases which might point to 
some catalyst deactivation. The induction period usually is related to the 
catalyst activation step by hydrogenation of the remaining bound COD, 
which can be very slow with some ligands (25-27). However, a similar 
profile would be obtained if the reaction was first order in substrate. At 
present, we have no kinetic data to support this theory. 
 Figure 4: Hydrogen uptake in the rhodium catalysed hydrogenation of 6 
at 5 bar with different ligands. 
So far we have not been able to glean much information from NMR 
experiments as broad absorptions were observed. We thus decided to use 
electrospray mass spectrometry to further investigate the rhodium species 
that are present during hydrogenation. Samples of a hydrogenation of 6 in 
CH2Cl2 using 5 mol% of [Rh(nbd)2]BF4/MonoPhos (5) (1:2) as catalyst 
at 1 bar H2 pressure were taken at regular intervals and examined by ES-
MS (Table III). 
Table III. Rhodium species observed with ES-MS in the 
hydrogenation of 6 with Rh(nbd)2BF4 /5.  
Time (min) Speciesa 
30  RhLS*, RhL2 (nbd), RhL2S*, RhL3, RhL3S  
60  RhLS*, RhL2(nbd), RhL2S*,  RhL3,  RhL4  
120  RhLS*, RhL2S*, RhL3,  RhL4  
* Small peaks. a Where L= ligand, S=substrate. 
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As can be seen from Table III the catalyst containing two ligands and 
1 norbornadiene (nbd) remains present in solution for at least 60 min; 
after 120 min it has disappeared completely. Its persistent presence might 
well be due to the poor mass-transfer in these magnetically stirred 
solutions. We have never experienced a lag-time in the hydrogenations 
that were performed at higher pressures in the autoclave. We also observe 
complexes containing 1, 2 or 3 ligands and 1 substrate molecule, however 
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these peaks are very small. The dependence of the rate on the hydrogen 
pressure confirms the fact that oxidative addition of hydrogen on the 
RhLn(Substrate) complex is the rate-determining step as in Halpern’s 
original proposal (19). The most important conclusion of this experiment 
is that part of the rhodium is locked up in complexes such as RhL3 or 
RhL4 that would not seem to be part of the catalytic cycle. The higher rate 
of hydrogenation when the L/Rh ratio is less than 2 might well be 
explained by a shift in this unfavorable equilibrium towards the lower 
ligated species. That these higher ligated rhodium species are present in 
substantial amounts was proven by the isolation of [Rh(5)4]BF4 as 
pentane/CH2Cl2 solvate crystals from one of the 1 bar hydrogenation 
experiments with L/Rh 2.2. The crystal structure is shown in Figure 5. 
The highly symmetrical structure of the square planar complex is 
remarkable. Surprisingly, the dimethylamino groups of all 4 ligands are 
located in the same hemisphere. The helical structure of one of the 
ligands is shown in Figure 6. We are currently performing kinetic 
experiments, which should allow us to determine the composition of the 
catalytic species. 
Figure 5: ORTEP representation of [Rh(5)4]BF4; hydrogen atoms are 
omitted for clarity. 
127 
Figure 6: Detail of ORTEP representation of complex [Rh(5)4]BF4 
showing one of the ligands with its helical shaped diol moiety. 
Summary 
Phosphoramidites are excellent ligands for rhodium-catalyzed 
asymmetric hydrogenations.  MonoPhos™ (5) provides the highest 
enantioselectivity in most cases for the synthesis of α-amino acid 
derivatives.  Although the exact nature of the catalytic species is not 
known, likely candidates are complexes with one or two phosphoramidite 
ligands attached to rhodium.  Work continues to understand the 
interactions between the ligands and metal. The reactions have been 
scaled up. 
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